Aunins John G. 4
4 · Seres Therapeutics, Inc. · Filed Jun 19, 2018
Insider Transaction Report
Form 4
Aunins John G.
CTO and EVP of Bioprocess Dev.
Transactions
- Exercise/Conversion
COMMON STOCK
2018-06-19+5,000→ 175,206 total - Exercise/Conversion
RESTRICTED STOCK UNITS
2018-06-19−5,000→ 10,000 total→ COMMON STOCK (5,000 underlying)
Footnotes (2)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]These restricted stock units have vested and settled or will vest and settle as to 25% of the restricted stock units on December 19, 2017, 25% on June 19, 2018; and 50% on December 19, 2018.